Prevention of percutaneous driveline infection after left ventricular assist device implantation: Prophylactic antibiotics are not necessary

John M. Stulak, Simon Maltais, Jennifer Cowger, Lyle D. Joyce, Richard C. Daly, Soon J. Park, Keith D. Aaronson, Francis D. Pagani

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Infection is a major source of morbidity and mortality after ventricular assist device (VAD) implantation. The percutaneous driveline is the most common site of infection in these patients and often serves as a portal to deeper pump infections. There are no data defining the role of prophylactic antibiotics in preventing these infections. We compared all patients who underwent primary HeartMate II VAD implantation at two different institutions employing two different driveline infection prevention strategies between February 2007 and September 2011. While all patients received perioperative antibiotics, driveline maintenance strategies included sterile dressing changes with Hibiclens application without continued prophylactic antibiotics (Abx) (Mayo Clinic, n = 141, No Abx) and sterile dressing changes with continued prophylactic antibiotics (University of Michigan Hospital, n = 144, Abx). Although gender was similar between cohorts (Abx: 79% male vs. No Abx: 84% male, p = 0.25), median age at implant (Abx: 59 vs. No Abx: 64, p = 0.001) and destination therapy as indication for VAD (Abx: 22% vs. No Abx: 60%, p < 0.001) were significantly different. Follow-up was available in all late survivors (Abx: 140 patients, No Abx: 127 patients). Median duration of support was similar between groups (Abx: 12.3 months vs. No Abx: 11 months, p = 0.44). Total patient-years of device support were 172 years for 140 patients in the Abx cohort and 146 years for 127 patients in the No Abx cohort. Driveline drainage/infection was observed in 25 of 140 patients (18%) in the Abx group and 16 of 127 (13%) in the No Abx group (p = 0.15). Device exchange for major driveline infection was performed in seven patients in the Abx group and 0 patients in the No Abx group. Total driveline infection events per patient-years of support were 0.15 for the Abx group and 0.11 in the No Abx group (p = 0.43). There was no significant difference in the raw incidence of major driveline infections or driveline infections per patient-years of support in patients who were maintained on prophylactic antibiotics compared with those who were not. These data suggest that other factors may be more important than prophylactic antibiotics in preventing driveline infections.

Original languageEnglish (US)
Pages (from-to)570-574
Number of pages5
JournalASAIO Journal
Volume59
Issue number6
DOIs
StatePublished - Nov 2013

Fingerprint

Left ventricular assist devices
Heart-Assist Devices
Antibiotics
Anti-Bacterial Agents
Infection
Drainage
Bandages
Pumps
Equipment and Supplies

Keywords

  • driveline
  • infection
  • mechanical circulatory support

ASJC Scopus subject areas

  • Biophysics
  • Biomaterials
  • Bioengineering
  • Biomedical Engineering
  • Medicine(all)

Cite this

Prevention of percutaneous driveline infection after left ventricular assist device implantation : Prophylactic antibiotics are not necessary. / Stulak, John M.; Maltais, Simon; Cowger, Jennifer; Joyce, Lyle D.; Daly, Richard C.; Park, Soon J.; Aaronson, Keith D.; Pagani, Francis D.

In: ASAIO Journal, Vol. 59, No. 6, 11.2013, p. 570-574.

Research output: Contribution to journalArticle

Stulak, John M. ; Maltais, Simon ; Cowger, Jennifer ; Joyce, Lyle D. ; Daly, Richard C. ; Park, Soon J. ; Aaronson, Keith D. ; Pagani, Francis D. / Prevention of percutaneous driveline infection after left ventricular assist device implantation : Prophylactic antibiotics are not necessary. In: ASAIO Journal. 2013 ; Vol. 59, No. 6. pp. 570-574.
@article{8ab004b64e8e4d1ab375542d84d50cbc,
title = "Prevention of percutaneous driveline infection after left ventricular assist device implantation: Prophylactic antibiotics are not necessary",
abstract = "Infection is a major source of morbidity and mortality after ventricular assist device (VAD) implantation. The percutaneous driveline is the most common site of infection in these patients and often serves as a portal to deeper pump infections. There are no data defining the role of prophylactic antibiotics in preventing these infections. We compared all patients who underwent primary HeartMate II VAD implantation at two different institutions employing two different driveline infection prevention strategies between February 2007 and September 2011. While all patients received perioperative antibiotics, driveline maintenance strategies included sterile dressing changes with Hibiclens application without continued prophylactic antibiotics (Abx) (Mayo Clinic, n = 141, No Abx) and sterile dressing changes with continued prophylactic antibiotics (University of Michigan Hospital, n = 144, Abx). Although gender was similar between cohorts (Abx: 79{\%} male vs. No Abx: 84{\%} male, p = 0.25), median age at implant (Abx: 59 vs. No Abx: 64, p = 0.001) and destination therapy as indication for VAD (Abx: 22{\%} vs. No Abx: 60{\%}, p < 0.001) were significantly different. Follow-up was available in all late survivors (Abx: 140 patients, No Abx: 127 patients). Median duration of support was similar between groups (Abx: 12.3 months vs. No Abx: 11 months, p = 0.44). Total patient-years of device support were 172 years for 140 patients in the Abx cohort and 146 years for 127 patients in the No Abx cohort. Driveline drainage/infection was observed in 25 of 140 patients (18{\%}) in the Abx group and 16 of 127 (13{\%}) in the No Abx group (p = 0.15). Device exchange for major driveline infection was performed in seven patients in the Abx group and 0 patients in the No Abx group. Total driveline infection events per patient-years of support were 0.15 for the Abx group and 0.11 in the No Abx group (p = 0.43). There was no significant difference in the raw incidence of major driveline infections or driveline infections per patient-years of support in patients who were maintained on prophylactic antibiotics compared with those who were not. These data suggest that other factors may be more important than prophylactic antibiotics in preventing driveline infections.",
keywords = "driveline, infection, mechanical circulatory support",
author = "Stulak, {John M.} and Simon Maltais and Jennifer Cowger and Joyce, {Lyle D.} and Daly, {Richard C.} and Park, {Soon J.} and Aaronson, {Keith D.} and Pagani, {Francis D.}",
year = "2013",
month = "11",
doi = "10.1097/MAT.0b013e3182a9e2a5",
language = "English (US)",
volume = "59",
pages = "570--574",
journal = "ASAIO Journal",
issn = "0162-1432",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Prevention of percutaneous driveline infection after left ventricular assist device implantation

T2 - Prophylactic antibiotics are not necessary

AU - Stulak, John M.

AU - Maltais, Simon

AU - Cowger, Jennifer

AU - Joyce, Lyle D.

AU - Daly, Richard C.

AU - Park, Soon J.

AU - Aaronson, Keith D.

AU - Pagani, Francis D.

PY - 2013/11

Y1 - 2013/11

N2 - Infection is a major source of morbidity and mortality after ventricular assist device (VAD) implantation. The percutaneous driveline is the most common site of infection in these patients and often serves as a portal to deeper pump infections. There are no data defining the role of prophylactic antibiotics in preventing these infections. We compared all patients who underwent primary HeartMate II VAD implantation at two different institutions employing two different driveline infection prevention strategies between February 2007 and September 2011. While all patients received perioperative antibiotics, driveline maintenance strategies included sterile dressing changes with Hibiclens application without continued prophylactic antibiotics (Abx) (Mayo Clinic, n = 141, No Abx) and sterile dressing changes with continued prophylactic antibiotics (University of Michigan Hospital, n = 144, Abx). Although gender was similar between cohorts (Abx: 79% male vs. No Abx: 84% male, p = 0.25), median age at implant (Abx: 59 vs. No Abx: 64, p = 0.001) and destination therapy as indication for VAD (Abx: 22% vs. No Abx: 60%, p < 0.001) were significantly different. Follow-up was available in all late survivors (Abx: 140 patients, No Abx: 127 patients). Median duration of support was similar between groups (Abx: 12.3 months vs. No Abx: 11 months, p = 0.44). Total patient-years of device support were 172 years for 140 patients in the Abx cohort and 146 years for 127 patients in the No Abx cohort. Driveline drainage/infection was observed in 25 of 140 patients (18%) in the Abx group and 16 of 127 (13%) in the No Abx group (p = 0.15). Device exchange for major driveline infection was performed in seven patients in the Abx group and 0 patients in the No Abx group. Total driveline infection events per patient-years of support were 0.15 for the Abx group and 0.11 in the No Abx group (p = 0.43). There was no significant difference in the raw incidence of major driveline infections or driveline infections per patient-years of support in patients who were maintained on prophylactic antibiotics compared with those who were not. These data suggest that other factors may be more important than prophylactic antibiotics in preventing driveline infections.

AB - Infection is a major source of morbidity and mortality after ventricular assist device (VAD) implantation. The percutaneous driveline is the most common site of infection in these patients and often serves as a portal to deeper pump infections. There are no data defining the role of prophylactic antibiotics in preventing these infections. We compared all patients who underwent primary HeartMate II VAD implantation at two different institutions employing two different driveline infection prevention strategies between February 2007 and September 2011. While all patients received perioperative antibiotics, driveline maintenance strategies included sterile dressing changes with Hibiclens application without continued prophylactic antibiotics (Abx) (Mayo Clinic, n = 141, No Abx) and sterile dressing changes with continued prophylactic antibiotics (University of Michigan Hospital, n = 144, Abx). Although gender was similar between cohorts (Abx: 79% male vs. No Abx: 84% male, p = 0.25), median age at implant (Abx: 59 vs. No Abx: 64, p = 0.001) and destination therapy as indication for VAD (Abx: 22% vs. No Abx: 60%, p < 0.001) were significantly different. Follow-up was available in all late survivors (Abx: 140 patients, No Abx: 127 patients). Median duration of support was similar between groups (Abx: 12.3 months vs. No Abx: 11 months, p = 0.44). Total patient-years of device support were 172 years for 140 patients in the Abx cohort and 146 years for 127 patients in the No Abx cohort. Driveline drainage/infection was observed in 25 of 140 patients (18%) in the Abx group and 16 of 127 (13%) in the No Abx group (p = 0.15). Device exchange for major driveline infection was performed in seven patients in the Abx group and 0 patients in the No Abx group. Total driveline infection events per patient-years of support were 0.15 for the Abx group and 0.11 in the No Abx group (p = 0.43). There was no significant difference in the raw incidence of major driveline infections or driveline infections per patient-years of support in patients who were maintained on prophylactic antibiotics compared with those who were not. These data suggest that other factors may be more important than prophylactic antibiotics in preventing driveline infections.

KW - driveline

KW - infection

KW - mechanical circulatory support

UR - http://www.scopus.com/inward/record.url?scp=84887221399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887221399&partnerID=8YFLogxK

U2 - 10.1097/MAT.0b013e3182a9e2a5

DO - 10.1097/MAT.0b013e3182a9e2a5

M3 - Article

C2 - 24172262

AN - SCOPUS:84887221399

VL - 59

SP - 570

EP - 574

JO - ASAIO Journal

JF - ASAIO Journal

SN - 0162-1432

IS - 6

ER -